港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

瑞博生物-B

58.800

-2.200-3.61%

成交量：27.22萬

成交額：1,543.53萬

市值：100.29億

市盈率：-31.70

高：59.800

開：59.000

低：54.000

收：61.000

52周最高：95.800

52周最低：54.000

股本：1.71億

香港流通股本：1.71億

量比：1.14

換手率：0.16%

股息：- -

股息率：- -

每股收益(LYR):-1.855

淨資產收益率：--

總資產收益率：--

市淨率：-151.26

市盈率(LYR):-31.70

市銷率: 49.06

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

瑞博生物-B03月03日主力淨流出70.8萬元散户資金買入

GSK乙肝新藥叩門上市，小核酸商業化拐點已至

瑞博生物-B啓動RBD7022注射液治療高脂血症III期臨床試驗

瑞博生物-B(06938)：RBD7022注射液即將於中國啓動用於治療高血脂症適應症的 III期臨床試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06938"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":58.8,"timestamp":1772611695096,"preClose":61,"halted":0,"volume":272200,"delay":0,"changeRate":-0.03606557377049185,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"未開盤","change":-2.2,"latestTime":"03-04 16:08:15","open":59,"high":59.8,"low":54,"amount":15435300,"amplitude":0.095082,"askPrice":58.8,"askSize":5400,"bidPrice":57.5,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61,"openAndCloseTimeList":[[1772587800000,1772596800000],[1772600400000,1772611200000]],"volumeRatio":1.141491,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-1.855,"volumeRatio":1.141491,"shares":170554910,"dividePrice":0,"high":59.8,"amplitude":0.095082,"preClose":61,"low":54,"week52Low":54,"pbRate":"-151.26","psRate":"49.06","week52High":95.8,"institutionHeld":0,"latestPrice":58.8,"committee":-0.636364,"eps":-1.855,"divideRate":0,"volume":272200,"delay":0,"ttmEps":-1.502,"open":59,"prevYearClose":57.97,"prevWeekClose":68.5,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":71.5,"twentyDayClose":68.8,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-03","current":-39.147803,"percent":1,"low":-50.513246,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"high":-41.67233,"avg":-47.34064,"sd":2.663177,"marketCap":10403849510},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-03","current":-41.67233,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"marketCap":10403849510}],"updateTime":1772643811405},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616043374","title":"瑞博生物-B03月03日主力淨流出70.8萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616043374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616043374?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:15","pubTimestamp":1772525757,"startTime":"0","endTime":"0","summary":"03月03日, 瑞博生物-B股价跌5.06%，报收61.00元，成交金额1771.5万元，换手率0.17%，振幅9.26%，量比1.30。瑞博生物-B今日主力资金净流出70.8万元，上一交易日主力净流入1308.1万元。该股近5个交易日下跌14.69%，主力资金累计净流入3623.3万元；近20日主力资金累计净流入3419.2万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2616188413","title":"GSK乙肝新藥叩門上市，小核酸商業化拐點已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2616188413","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616188413?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 19:05","pubTimestamp":1772449503,"startTime":"0","endTime":"0","summary":"截至目前，Alnylam已形成7款商业化产品梯队。英克司兰钠是全球首个siRNA降脂药，也是首款面向常见慢性病的小核酸药物，它的成功具有里程碑意义。这些技术创新，共同驱动小核酸药物治疗潜力不断释放，推动市场进入加速增长通道。2月23日，前沿生物与GSK达成独家授权协议，GSK获得两款siRNA管线全球开发、生产及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1165985607","title":"瑞博生物-B啓動RBD7022注射液治療高脂血症III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165985607","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165985607?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410268,"startTime":"0","endTime":"0","summary":"瑞博生物-B（股票代码：06938）近日宣布，其研发的RBD7022注射液将在中国正式启动针对高脂血症治疗的III期临床试验。该试验旨在进一步评估该药物在更广泛患者群体中的安全性与有效性，标志着其在心血管代谢疾病治疗领域的研发进程迈入关键阶段。高脂血症作为常见的心血管风险因素，其创新疗法的推进备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2616877702","title":"瑞博生物-B(06938)：RBD7022注射液即將於中國啓動用於治療高血脂症適應症的 III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616877702?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，集团自主研发的RBD7022注射液已由合作方齐鲁制药有限公司(齐鲁制药)完成III期临床试验登记公示，即将启动III期临床试验。RBD7022注射液是一款靶向PCSK9的siRNA药物。PCSK9是一种酶，在调节体内胆固醇，尤其是通常被称为“LDL-C”或“坏胆固醇”的低密度脂蛋白(LDL)胆固醇的水平方面起关键作用，可作为管理高胆固醇血症的一种治疗选择，旨在降低与高胆固醇水平相关的心血管疾病风险。2023年12月，公司将RBD7022注射液在中国内地、中国香港和中国澳门开发、生产和商业化的独家权利授予齐鲁制药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","06938","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":23,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/06938\",params:#limit:6,delay:false,,,undefined,":[]}}